C-Met as a molecular marker for esophageal squamous cell carcinoma and its association with clinical outcome

Journal of Cancer

Volumn 7, Issue 5, 2016, Pages 587-594

  Xu, Ya Ping ^a,b   Lin, Gang ^c   Sun, Xiao Jiang ^b   Yan, Mao Hui ^b   Zhang, Gu ^b   Hu, Jin Lin ^b   Sun, Wen Yong ^b   Yu, Jin Ming ^d  

^a SHANDONG UNIVERSITY   (China)

^b ZHEJIANG CANCER HOSPITAL   (China)

^c WENZHOU MEDICAL UNIVERSITY   (China)

^d SHANDONG CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

C MET; Human epidermal growth factor receptor 2; Epidermal growth factor receptor; Esophageal squamous cell carcinoma

Indexed keywords

EID: 84971554654     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.13687     Document Type: Article

References (32)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69-90.
2. Tepper J, Krasna MJ, Niedzwiecki D, Hollis D, Reed CE, Goldberg R, et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol. 2008;26:1086-92.
3. Shang L, Liu HJ, Hao JJ, Jiang YY, Shi F, Zhang Y, et al. A panel of overexpressed proteins for prognosis in esophageal squamous cell carcinoma. PloS one. 2014;9:e111045.
4. Kato H, Arao T, Matsumoto K, Fujita Y, Kimura H, Hayashi H, et al. Gene amplification of EGFR, HER2, FGFR2 and MET in esophageal squamous cell carcinoma. Int J Oncol. 2013;42:1151-8.
5. Hanawa M, Suzuki S, Dobashi Y, Yamane T, Kono K, Enomoto N, et al. EGFR protein overexpression and gene amplification in squamous cell carcinomas of the esophagus. Int J Cancer. 2006;118:1173-80.
6. Jiang D, Li X, Wang H, Shi Y, Xu C, Lu S, et al. The prognostic value of EGFR overexpression and amplification in Esophageal squamous cell Carcinoma. BMC cancer. 2015;15:377.
7. Li JC, Zhao YH, Wang XY, Yang Y, Pan DL, Qiu ZD, et al. Clinical significance of the expression of EGFR signaling pathway-related proteins in esophageal squamous cell carcinoma. Tumour Biol. 2014 Jan;35:651-7.
8. Delektorskaya VV, Chemeris GY, Zavalishina LE, Ryazantseva AA, Grigorchuk AY, Kononets PV, et al. Squamous cell carcinoma of the esophagus: evaluation of the status of epidermal growth factor receptors (EGFR and HER-2) by immunohistochemistry and in situ hybridization. Bull Exp Biol Med. 2010;149:615-20.
9. Zhang W, Zhu H, Liu X, Wang Q, Zhang X, He J, et al. Epidermal growth factor receptor is a prognosis predictor in patients with esophageal squamous cell carcinoma. Ann Thorac Surg. 2014;98:513-9.
10. Fukai Y, Masuda N, Kato H, Fukuchi M, Miyazaki T, Nakajima M, et al. Correlation between laminin-5 gamma2 chain and epidermal growth factor receptor expression in esophageal squamous cell carcinomas. Oncology. 2005;69:71-80.
11. Yu WW, Guo YM, Zhu M, Cai XW, Zhu ZF, Zhao WX, et al. Clinicopathological and prognostic significance of EGFR over-expression in esophageal squamous cell carcinoma: a meta-analysis. Hepato-gastroenterology. 2011;58:426-31.
12. Xu Y, Peng Z, Li Z, Lu M, Gao J, Li Y, et al. Expression and clinical significance of c-Met in advanced esophageal squamous cell carcinoma. BMC cancer. 2015;15:6.
13. Ozawa Y, Nakamura Y, Fujishima F, Felizola SJ, Takeda K, Okamoto H, et al. c-Met in esophageal squamous cell carcinoma: an independent prognostic factor and potential therapeutic target. BMC cancer. 2015;15:451.
14. Jardim DL, de Melo Gagliato D, Falchook GS, Janku F, Zinner R, Wheler JJ, et al. MET aberrations and c-Met inhibitors in patients with gastric and esophageal cancers in a phase I unit. Oncotarget. 2014;5:1837-45.
15. Betts G, Valentine H, Pritchard S, Swindell R, Williams V, Morgan S, et al. FGFR2, HER2 and cMet in gastric adenocarcinoma: detection, prognostic significance and assessment of downstream pathway activation. Virchows Arch. 2014;464:145-56.
16. Mhawech-Fauceglia P, Afkhami M, Pejovic T. MET/HGF Signaling Pathway in Ovarian Carcinoma: Clinical Implications and Future Direction. Patholog Res Int. 2012;2012:960327.
17. Samame Perez-Vargas JC, Biondani P, Maggi C, Gariboldi M, Gloghini A, Inno A, et al. Role of cMET in the development and progression of colorectal cancer. Int J Mol Sci. 2013;14:18056-77.
18. Matsumoto K, Nakamura T. Hepatocyte growth factor: renotropic role and potential therapeutics for renal diseases. Kidney Int. 2001;59:2023-38.
19. Mesteri I, Schoppmann SF, Preusser M, Birner P. Overexpression of CMET is associated with signal transducer and activator of transcription 3 activation and diminished prognosis in oesophageal adenocarcinoma but not in squamous cell carcinoma. Eur J Cancer. 2014;50:1354-60.
20. Hechtman JF, Polydorides AD. HER2/neu gene amplification and protein overexpression in gastric and gastroesophageal junction adenocarcinoma: a review of histopathology, diagnostic testing, and clinical implications. Arch Pathol Lab Med. 2012;136:691-7.
21. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687-97.
22. Reichelt U, Duesedau P, Tsourlakis M, Quaas A, Link BC, Schurr PG, et al. Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus. Mod Pathol. 2007;20:120-9.
23. Schoppmann SF, Jesch B, Friedrich J, Wrba F, Schultheis A, Pluschnig U, et al. Expression of Her-2 in carcinomas of the esophagus. Am J Surg Pathol. 2010;34:1868-73.
24. Dreilich M, Wanders A, Brattstrom D, Bergstrom S, Hesselius P, Wagenius G, et al. HER-2 overexpression (3+) in patients with squamous cell esophageal carcinoma correlates with poorer survival. Dis Esophagus. 2006;19:224-31.
25. Hofmann M, Stoss O, Shi D, et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology. 2008;52:797-805.
26. Moelans CB, van Diest PJ, Milne AN, Offerhaus GJ. Her-2/neu testing and therapy in gastroesophageal adenocarcinoma. Patholog Res Int. 2011;2011:674182.
27. Sato-Kuwabara Y, Neves JI, Fregnani JH, Sallum RA, Soares FA. Evaluation of gene amplification and protein expression of HER-2/neu in esophageal squamous cell carcinoma using Fluorescence in situ Hybridization (FISH) and immunohistochemistry. BMC cancer. 2009;9:6.
28. GANG LIN, XIAO-JIANG SUN, QIAN-BO HAN, et al. Epidermal growth factor receptor protein overexpression and gene amplification are associated with aggressive biological behaviors of esophageal squamous cell carcinoma. Oncology letters. 2015; in press.
29. Almhanna K, Meredith KL, Hoffe SE, Shridhar R, Coppola D. Targeting the human epidermal growth factor receptor 2 in esophageal cancer. Cancer Control. 2013;20:111-6.
30. Cappellesso R, Fassan M, Hanspeter E, et al. HER2 status in gastroesophageal cancer: a tissue microarray study of 1040 cases. Hum Pathol. 2015;46:665-72.
31. Kawaguchi Y, Kono K, Mimura K, et al. Targeting EGFR and HER-2 with cetuximab-and trastuzumab-mediated immunotherapy in oesophageal squamous cell carcinoma. Br J Cancer. 2007;97:494-501.
32. Lorenzen S, Riera Knorrenschild J, Haag GM, Pohl M, et al. Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer: a randomised phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. Eur J Cancer. 2015;51:569-76.